SG10201407403UA - Treatments For Gastrointestinal Disorders - Google Patents

Treatments For Gastrointestinal Disorders

Info

Publication number
SG10201407403UA
SG10201407403UA SG10201407403UA SG10201407403UA SG10201407403UA SG 10201407403U A SG10201407403U A SG 10201407403UA SG 10201407403U A SG10201407403U A SG 10201407403UA SG 10201407403U A SG10201407403U A SG 10201407403UA SG 10201407403U A SG10201407403U A SG 10201407403UA
Authority
SG
Singapore
Prior art keywords
gastrointestinal disorders
treatments
present
pharmaceutical compositions
gastrointestinal
Prior art date
Application number
SG10201407403UA
Other languages
English (en)
Inventor
Mark G Currie
Angelika Fretzen
Marco Kessler
Daniel P Zimmer
Original Assignee
Ironwood Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503086&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201407403U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ironwood Pharmaceuticals Inc filed Critical Ironwood Pharmaceuticals Inc
Publication of SG10201407403UA publication Critical patent/SG10201407403UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
SG10201407403UA 2009-11-09 2010-11-09 Treatments For Gastrointestinal Disorders SG10201407403UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25926409P 2009-11-09 2009-11-09

Publications (1)

Publication Number Publication Date
SG10201407403UA true SG10201407403UA (en) 2014-12-30

Family

ID=43503086

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201407403UA SG10201407403UA (en) 2009-11-09 2010-11-09 Treatments For Gastrointestinal Disorders

Country Status (25)

Country Link
US (3) US20140179607A9 (fr)
EP (1) EP2499154B1 (fr)
JP (1) JP5913115B2 (fr)
KR (1) KR20120115495A (fr)
CN (1) CN102812038B (fr)
AR (1) AR078950A1 (fr)
AU (1) AU2010314866B2 (fr)
BR (1) BR112012011730A2 (fr)
CA (1) CA2779482A1 (fr)
CL (1) CL2012001186A1 (fr)
CO (1) CO6551683A2 (fr)
CR (1) CR20120303A (fr)
EA (1) EA022817B1 (fr)
EC (1) ECSP12011962A (fr)
ES (1) ES2620153T3 (fr)
GE (1) GEP20166435B (fr)
IL (1) IL219596A0 (fr)
MX (2) MX350046B (fr)
NZ (1) NZ599751A (fr)
SG (1) SG10201407403UA (fr)
TW (1) TWI482626B (fr)
UA (1) UA114274C2 (fr)
UY (2) UY33017A (fr)
WO (1) WO2011057272A1 (fr)
ZA (1) ZA201203342B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2930674A1 (fr) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
US20120028897A1 (en) * 2008-12-02 2012-02-02 Currie Mark G Methods and compositions for the treatment of fluid retention disorders
AU2010314866B2 (en) * 2009-11-09 2014-10-30 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
CN102822194B (zh) * 2009-12-07 2016-10-26 硬木药品公司 用于胃肠病症的治疗
WO2012155114A1 (fr) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Nouveaux dérivés d'uroguanyline et leur utilisation pour le traitement des troubles gastro-intestinaux
US20160213739A1 (en) * 2011-05-11 2016-07-28 Ironwood Pharmaceuticals, Inc Treatments for disorders using guanylate cyclase c agonists
US9650417B2 (en) * 2011-05-11 2017-05-16 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
US9617305B2 (en) 2011-06-08 2017-04-11 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170766A1 (fr) * 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Traitements de troubles gastro-intestinaux
WO2013025969A1 (fr) * 2011-08-17 2013-02-21 Ironwood Pharmaceuticals, Inc. Traitements pour des troubles gastro-intestinaux
WO2014088623A1 (fr) * 2012-07-12 2014-06-12 Forest Laboratories Holdings Limited Compositions de linaclotide
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
NZ717739A (en) 2013-08-09 2023-12-22 Ardelyx Inc Compounds and methods for inhibiting phosphate transport
CA2926685A1 (fr) * 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonistes de guanylate cyclase utiles pour la regulation negative de cytokines pro-inflammatoires
WO2016015055A1 (fr) * 2014-07-25 2016-01-28 Ironwood Pharmaceuticals, Inc. Compositions de nettoyage du côlon
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB290795A (en) 1927-04-08 1928-05-24 British Colour Printing Compan Improvements in or relating to advertising or display devices
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5601990A (en) * 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5962220A (en) * 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US5518888A (en) * 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US6060037A (en) * 1993-10-26 2000-05-09 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
AU2001256315A1 (en) * 2000-04-22 2001-11-07 Ipf Pharmaceuticals Gmbh Use of guanylate cyclase-c (gc-c) agonists as insulinotropic factors for treating diabetes type 2
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) * 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN100589839C (zh) * 2003-01-28 2010-02-17 艾恩伍德医药品股份有限公司 多肽及包含多肽的药物组合物
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2007022531A2 (fr) 2005-08-19 2007-02-22 Microbia, Inc. Compositions et methodes de traitement de troubles gastro-intestinaux
AU2008261102B2 (en) * 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
PE20151205A1 (es) * 2008-08-15 2015-08-31 Ironwood Pharmaceuticals Inc Formulaciones que contienen linaclotida para administracion oral
WO2010027405A2 (fr) * 2008-09-04 2010-03-11 Ironwood Pharmaceuticals, Inc. Formulations solides stables de polypeptides agonistes vis-à-vis du récepteur gc-c se prêtant à une administration par voie orale
AU2010314866B2 (en) * 2009-11-09 2014-10-30 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2011156453A2 (fr) 2010-06-09 2011-12-15 Combimab, Inc. Peptides thérapeutiques

Also Published As

Publication number Publication date
EP2499154A1 (fr) 2012-09-19
US20130085107A1 (en) 2013-04-04
US20140179607A9 (en) 2014-06-26
AU2010314866A1 (en) 2012-05-31
US8946158B2 (en) 2015-02-03
BR112012011730A2 (pt) 2016-03-08
MX2012005368A (es) 2012-06-13
UY33018A (es) 2011-01-31
MX350046B (es) 2017-08-24
EA022817B1 (ru) 2016-03-31
CN102812038A (zh) 2012-12-05
CO6551683A2 (es) 2012-10-31
UA114274C2 (uk) 2017-05-25
EA201290322A1 (ru) 2013-01-30
NZ599751A (en) 2014-08-29
ES2620153T3 (es) 2017-06-27
ZA201203342B (en) 2013-01-30
ECSP12011962A (es) 2012-07-31
CA2779482A1 (fr) 2011-05-12
TW201116291A (en) 2011-05-16
GEP20166435B (en) 2016-02-25
WO2011057272A1 (fr) 2011-05-12
UY33017A (es) 2011-06-30
JP2013510182A (ja) 2013-03-21
US20110118184A1 (en) 2011-05-19
CN102812038B (zh) 2016-05-18
KR20120115495A (ko) 2012-10-18
CR20120303A (es) 2012-08-08
CL2012001186A1 (es) 2013-07-12
US20140024593A1 (en) 2014-01-23
US8507447B2 (en) 2013-08-13
EP2499154B1 (fr) 2016-12-21
IL219596A0 (en) 2012-06-28
AR078950A1 (es) 2011-12-14
TWI482626B (zh) 2015-05-01
AU2010314866B2 (en) 2014-10-30
JP5913115B2 (ja) 2016-05-11

Similar Documents

Publication Publication Date Title
SG10201407403UA (en) Treatments For Gastrointestinal Disorders
EP2440210A4 (fr) Procédés de traitement de troubles gastro-intestinaux
NZ593474A (en) Compositions and methods for treatment of celiac disease
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
IN2012DN03310A (fr)
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
MY173994A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX342643B (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
WO2009114461A3 (fr) Formes pharmaceutiques d'angiotensine (1-7) et leur utilisation
MY150931A (en) Substituted oxazolidinones and their use
WO2010135521A3 (fr) Compositions et procédés pour le traitement et le diagnostic de la grippe
EA201200428A1 (ru) Композиция и способ для лечения ожирения
MX2022013283A (es) Composiciones para limpieza de colon y tratamiento de trastornos gastrointestinales.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MY169574A (en) Vaccine therapy